STCO yields 2000000.00% · ABBV yields 3.06%● Live data
📍 STCO pulled ahead of the other in Year 1
Combined, STCO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STCO + ABBV for your $10,000?
StratoComm Corporation engages in the development and provision of telecommunications infrastructure technologies worldwide. The company offers transitional telecommunications system, a wireless telecommunications system that would provide various real-time and non-real-time multimedia services and applications, including voice over Internet protocol (IP); Web browsing/news groups/e-mail; tele-medicine/distance learning; videoconferencing, video telephony, and audio conferencing; tele-shopping/tele-banking; interactive gaming; collaborative working; push applications; IP multicast streaming; IPTV with distributed interactive television; video broadcasting on demand; virtual private networking; and LAN interconnection. It also provides solar-powered lighter-than-air vehicle that operates over rural or metropolitan areas, which delivers mobile, broadband, narrowband, and fiber optic speed wireless backbone telecommunication services. In addition, StratoComm Corporation offers stratospheric telecommunications system that delivers various services, such as voice, broadband, and broadcast. The company was formerly known as US/Africa Ventures, Inc. and changed its name to StratoComm Corporation. StratoComm Corporation was founded in 1992 and is headquartered in Albany, New York.
Full STCO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.